SCOLR Pharma, Inc. (DDD) is a publicly traded company in the Unknown sector. Across all available filings, 47 corporate insiders have executed 1010 transactions totaling $133.2M, demonstrating a bearish sentiment with -$120.5M in net insider flow. The most recent transaction on Dec 12, 2025 involved a transaction of 5,212 shares valued at $9.9K.
No significant insider buying has been recorded for DDD in the recent period.
No significant insider selling has been recorded for DDD in the recent period.
Based on recent SEC filings, insider sentiment for DDD is bearish with an Insider Alignment Score of 5/100 and a net flow of -$120.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at SCOLR Pharma, Inc. (DDD) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 47 insiders are actively trading DDD stock, having executed 1010 transactions in the past 90 days. The most active insider is G. Walter Loewenbaum II (Executive), who has made 110 transactions totaling $53.7M.
Get notified when executives and directors at DDD file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | R. Zuiker Joseph | Executive | Payment | 5,212 | $1.90 | $9.9K | |
| Dec 2, 2025 | B. Nordstrom Phyllis | Executive | Payment | 1,729 | $2.04 | $3.5K | |
| Sep 16, 2025 | Drayton Claudia | Executive | Award | 29,069 | $N/A | $0 | |
| Sep 5, 2025 | A. Graves Jeffrey | Executive | Payment | 40,125 | $2.12 | $85.1K | |
| Sep 5, 2025 | Puthenveetil Reji | Executive | Payment | 16,050 | $2.12 | $34.0K | |
| Sep 5, 2025 | B. Nordstrom Phyllis | Executive | Payment | 13,389 | $2.12 | $28.4K | |
| Sep 5, 2025 | B. Nordstrom Phyllis | Executive | Award | 414,507 | $N/A | $0 | |
| Sep 5, 2025 | R. Zuiker Joseph | Executive | Payment | 6,733 | $2.12 | $14.3K | |
| Sep 5, 2025 | W. Hull Charles | Executive | Payment | 4,929 | $2.12 | $10.4K | |
| Sep 5, 2025 | William Banasick Wright Andrew | Executive | Payment | 5,856 | $2.12 | $12.4K | |
| Sep 5, 2024 | A. Graves Jeffrey | Executive | Award | 247,933 | $N/A | $0 | |
| Sep 5, 2024 | D. Creech Jeffrey | Executive | Award | 82,644 | $N/A | $0 | |
| Sep 5, 2024 | Puthenveetil Reji | Executive | Award | 99,173 | $N/A | $0 | |
| Sep 5, 2024 | B. Nordstrom Phyllis | Executive | Award | 82,644 | $N/A | $0 | |
| Sep 5, 2024 | R. Zuiker Joseph | Executive | Award | 66,115 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 397 | $126.9M | 80.0% |
Payment(F) | 194 | $20.9M | 13.2% |
Purchase(P) | 56 | $6.3M | 4.0% |
Other(J) | 22 | $2.0M | 1.3% |
Award(A) | 304 | $2.0M | 1.3% |
Exercise(M) | 2 | $275.6K | 0.2% |
Disposition(D) | 6 | $99.0K | 0.1% |
Gift(G) | 29 | $0 | 0.0% |
Insider selling pressure at SCOLR Pharma, Inc. has increased, with 47 insiders executing 1010 transactions across all time. Total sales of $126.9M significantly outpace purchases of $6.3M, resulting in a net outflow of $120.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.